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Abstract
Cystic Fibrosis (CF) is a common autosomal recessive disorder, caused by mutations
in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. CFTR
gene expression is tightly controlled by transcriptional and post-transcriptional
regulatory factors, resulting in complex spatial and temporal expression patterns.
Here, we describe an overview of the findings about the contribution of ncRNAs,
especially miRNAs, in physiological CFTR gene expression and in CF. Determination
of mechanisms governing its expression is essential for developing new CF therapies.
ncRNAs, including lncRNAs and miRNAs, could also contribute to CF progression
and severity and their dysregulation in CF opens new perspectives for patient follow-
up and treatment.
Keywords: CFTR gene expression, Cystic Fibrosis, non-coding RNA, lncRNA, miR‐
NA
1. Introduction
Cystic Fibrosis (CF) is a common autosomal recessive disorder. Although in its classical form
CF affects several organs, including the pancreas and the gastrointestinal and reproductive
tracts, its morbidity is mainly due to pulmonary damages. This disorder is caused by mutations
in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. This gene displays
great mutational heterogeneity, depending on the ethnic and phenotypic background, with
almost 2,000 referenced CFTR alterations (genet.sickkids.on.ca/). The most common mutation
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
is the p.Phe508del, whereas other mutations, located both in coding and non-coding regions,
are rare or private. The p.Phe508del mutation induces aberrant protein folding, leading to
endoplasmic reticulum (ER)-associated degradation, atypical intracellular trafficking and
reduced stability of the CFTR protein at the apical membrane. Dysfunction or lack of the CFTR
protein causes an obstructive lung disease characterized by impaired ion transport in the
airway epithelium, accumulation of sticky mucus in the air space and chronic airway inflam‐
mation. Physiological CFTR expression is tightly controlled by transcriptional, post-transcrip‐
tional, translational and post-translational regulatory mechanisms, resulting in complex
spatial and temporal expression patterns. Notwithstanding the importance of CFTR transcrip‐
tional regulation [1-3], CFTR expression can be modulated through other mechanisms. Indeed,
epigenetic changes, such as DNA methylation or histone acetylation, also influence CFTR gene
expression in different tissues [4-7]. Post-transcriptional controls also regulate its expression,
for instance via the usage of upstream open reading frames (uORFs) encoded within the CFTR
5’UTR [8] and the 3’UTR that controls CFTR mRNA stability through ARE sequences (AU-rich
elements) [9]. An emerging area of research is focusing on the role played by non-coding RNAs
(ncRNAs), such as microRNAs (miRNAs), in CFTR gene expression. Starting from 2011, a few
studies have shown the involvement of miRNAs in the physiological control of the complex
spatio-temporal expression pattern of CFTR mRNA [10,11], including a recent work by our
group [3]. Moreover, the implication of long non-coding RNAs (lncRNAs) and miRNAs in
human diseases is well documented [12], including in inherited disorders [13] and lung
diseases [14-17]. However, only few studies, described below, have hitherto been carried out
on the role of ncRNAs in CF. This chapter is an overview of the findings about the role of
ncRNAs in physiological CFTR gene expression and in CF.
2. What are non-coding RNAs?
Large expanses of the genome are transcribed into RNAs, but only a small portion of these
RNAs encode proteins [18,19]. Many fundamental cellular processes rely on conserved
ncRNAs, particularly on ribosomal RNAs (rRNAs), the ribosome RNA components that allow
mRNA translation into proteins (Figure 1). Other roles are the transport of amino acids via
transfer RNAs (tRNAs) and mRNA splicing through the implication of small nucleolar RNAs
(snoRNAs). miRNAs and their crucial role as key modulators of post-transcriptional gene
regulation were discovered more than 20 years ago [20]. In the last few years, lncRNAs have
been identified as new modulators of key biological processes [21-23, 18]. Currently, ncRNAs
are divided in two classes, based on their length; long ncRNAs (lncRNAs, > 200 nt) and short
ncRNAs (<200 nt), such as miRNAs, small nucleolar RNAs (snoRNAs) and PIWI-interacting
RNAs (piRNAs) [24].
Ribosomal RNA (rRNA) and transfer RNA (tRNA) are the most represented ncRNAs in
humans. Long non-coding RNAs (lnc or long ncRNA) are longer than 200 nt and are subdi‐
vided in five categories based on their genomic localization: pRNA (promoter-associated
RNA), eRNA (enhancer-associated RNA), gsRNA (gene body-associated RNA), lincRNA
(intergenic RNA) and NAT (Natural Antisense Transcript). Short non-coding RNAs (short
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ncRNAs) are smaller than 200 nt and are subdivided in four classes based on their size and
function: siRNA (small interfering RNA), miRNA (microRNA), piRNA (PIWI-interacting
RNA), snoRNA (small nucleolar RNA) and derived snoRNA (sdRNA).
2.1. Long non-coding RNAs
lncRNAs include all ncRNAs longer than 200 nt (except rRNA and tRNA). They constitute the
bulk of the non-coding transcriptome [25].
2.1.1. lncRNA biogenesis
It is thought that most lncRNAs originate within a 2-kb region surrounding the Transcription
Start Site (TSS) of protein-coding genes (65% of lncRNAs overlap with a promoter and are
called pRNAs), or map to enhancer regions (19%; named eRNAs), or derive from antisense
transcripts that overlap with annotated gene bodies (5%, called NATs), or are associated with
the bodies of protein-coding genes (gsRNA, gene body-associated lncRNAs) [26, 27]. The
remaining lncRNAs originate from more distal (>2kb) unannotated regions (11%) and are
commonly referred to as long intervening or intergenic ncRNAs (lincRNAs) [28, 29] (Figure 2).
a-Promoter-associated RNAs (pRNA), b-Enhancer-associated RNAs (eRNA), c-Intronic and
gene body-associated (sense) RNAs (gsRNA), d-Natural Antisense Transcripts (NAT), e-Long
Intergenic RNAs (lincRNA). In the lower part of the figure are described the main lncRNA
functions.
Figure 1. Non-coding RNAs.
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The finding that a large number of lncRNAs arise from loci close to protein-coding genes is
consistent with previous genome-wide analyses of lncRNAs [30]. Although all studies agree
that the 5′end of lncRNAs, like for mRNAs, is capped by methylguanosine, their splicing status
and their 3′-end processing have not been fully defined [26]. It is likely that splice site recog‐
nition occurs at low frequency at most lncRNA loci and that lncRNAs may be predominantly
mono-exonic and non-polyadenylated [26]. Most lncRNAs are not translated [28] and their
localization is predominantly nuclear [25].
2.1.2. lncRNA functions
lncRNAs have regulatory functions in different biological processes (Figure 2). Many of their
functions are related to their capacity to bind to RNA, DNA and proteins. The founding
member of the lncRNA family is Xist (~17 kb). Xist originates from the silent X chromosome
in female cells and coats this chromosome during the early stages of development to establish
epigenetic X inactivation [31]. lncRNAs can be used as indicators of the transcriptional activity
of a locus or a gene [19]. Their roles as scaffolds for nuclear processes, guides for ribonucleo‐
protein complexes or decoys have been described in the literature. Similarly to miRNAs, they
can act as activators or repressors of protein expression.
Figure 2. lncRNAs, from biogenesis to functions.
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lncRNAs are considered to be more species, tissue and developmental stage-specific than
mRNAs [32]. A growing number of studies show that lncRNA deregulation has a role in
various diseases [33,34; for reviews: 35,36], including pulmonary disorders. Several reviews
have discussed the role of lncRNAs and miRNAs in respiratory diseases [16,17,37] and a recent
work reported lncRNA involvement in CF (detailed in section 4.2.1).
2.2. MicroRNAs
2.2.1. miRNA localization and biogenesis
Animal miRNAs derive from the nuclear genome. In humans, the majority of canonical
miRNAs are encoded by introns of non-coding or coding transcripts, but some miRNAs are
encoded by exonic regions (Figure 3). Often, several miRNA loci are in close proximity, thus
constituting a polycistronic transcription unit [38]. Most miRNAs use their host gene tran‐
scripts as carriers, but separate transcription from internal promoters remains possible.
Generally, miRNAs in the same cluster are co-transcribed. Most miRNA genes located in
introns of protein-coding genes share the promoter of the host gene [39]. miRNA genes often
have multiple transcription start sites [40]. miRNA loci in intergenic regions apparently have
their own transcriptional regulatory elements, thus constituting independent transcription
units.
miRNA gene 
Gene 1 Gene 2 
Intergenic 
Intronic Exonic 
Intragenic 
Cluster Isolated 
OR 
Figure 3. Genomic locations of miRNAs. miRNA genes, isolated or in clusters, are located in intergenic (ex: miR-494) or
intragenic genome regions, including exons of non-coding (e.g. miR-155) or coding (e.g. miR-985) genes and introns of
non-coding (e.g. the miR-15a ~16-1 cluster) or coding (e.g. miR-126) genes.
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miRNA biogenesis includes several steps. First, the gene coding for a given miRNA is
transcribed by RNA polymerase II into a long primary transcript (pri-miRNA, ranging from
100 nt to several kilobases). Some miRNA genes, especially those located in Alu elements, are
transcribed by RNA polymerase III [41]. When several miRNAs are in a cluster, pri-miRNAs
can contain multiple miRNAs. Transcription factors, such as p53, MYC, C/EBP, FOXA
positively or negatively regulate miRNA transcription [3,42,43]. Epigenetic control, such as
DNA methylation and histone modifications also contribute to miRNA gene regulation [44].
Then, several maturation steps are necessary for miRNA processing. Indeed, the long pri-
miRNAs (typically over 1kb) contain stem–loop structures in which mature miRNA sequences
are embedded. The nuclear RNase III Drosha acts by cropping the stem–loop to release small
hairpin-shaped RNAs of 65 nt in length (pre-miRNA) from the pri-miRNAs. To do this, Drosha,
together with its cofactor DiGeorge Syndrome Critical Region 8 (DGCR8), forms the Micro‐
processor complex. As Drosha cleavage defines one end of the mature miRNA and thereby
determines its specificity, it is important that the Microprocessor complex precisely recognizes
and cleaves each pri-miRNA. Importantly, Drosha-mediated processing of intronic miRNAs
does not affect splicing of the host pre-miRNA [45]. Multiple auxiliary factors could contribute
to pri-miRNA maturation [46]. For example, three primary sequence determinants (the basal
UG, CNNC and the apical GUG motifs) contribute to efficient processing of human pri-
miRNAs. At least one of these three motifs is present in almost 80% of human miRNAs [46].
The splicing factor SRp20 (also called SRSF3) and the RNA helicase DDX17 bind to the CNNC
motif and increase processing of human pri-miRNAs by Drosha. Moreover, the terminal loops
of miRNA precursors are enriched in cis-elements that recruit regulatory proteins. For
example, the splicing factors HNRPA1 and KSRP bind to the conserved terminal loops of some
pri-miRNAs and facilitate Drosha-mediated processing [47-49].
Following Drosha processing, pre-miRNAs are exported in the cytoplasm where they are
cleaved by Dicer near the terminal loop, liberating a small RNA duplex. Dicer, like Drosha,
belongs to a family of RNase III-type endonucleases that act specifically on double-stranded
RNA.
RNA duplexes include two mature miRNAs: one derived from the 5ʹ strand and the other one
from the 3ʹ strand of the precursor (e.g. miR-27a-5p and miR-27a-3p). One is also called the
‘guide’ (miRNA) and is usually more biologically active than the other one (the ‘passenger’,
often referred to as miRNA*). The passenger is normally degraded, but, in some cases, it can
be functional [50]. The mature miRNA strand is subsequently incorporated in the RNA-
induced silencing complex (RISC, or miRISC for miRNA-containing RISC, or miRNP for
microribonucleoprotein), where it directly binds to a member of the Argonaute (AGO) protein
family (four AGO members, AGO1 are the most frequently used).
To date, about 1,900 miRNAs (1,881 precursors and 2,588 mature miRNAs; GRCh38 human
genome assembly) have been reported in the miRbase database (http://www.mirbase.org/). A
substantial number of these miRNAs have dubious annotations and for nearly one-third of
miRNA loci, there is no convincing evidence concerning the production of authentic miRNAs
(miRbase).
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2.2.2. miRNA roles
miRNAs are small ncRNAs that can act in the nucleus and in the cytoplasm [51] through
binding to RNA, DNA and proteins. They play an important role in the negative regulation of
gene expression by base-pairing to partially complementary sites on the target mRNAs,
usually in the 3’ UTR part. Binding of an miRNA to its target mRNA, within the RISC complex,
typically leads to translational repression and exonucleolytic mRNA decay. However, highly
complementary targets can be cleaved endonucleolytically.
Figure 4. Main miRNA roles. a. Translation block by inhibiting cap and poly(A)-binding protein recognition. b. Elon‐
gation inhibition by slowing down elongation or ribosome ‘drop-off’. c. Degradation by deadenylation and decapping.
d. Proteolysis. Degradation of a nascent peptide. e. mRNA storage in P-bodies that contain exonucleases, RNA helicas‐
es, decapping enzymes, DCP1/2, exosomes, deadenylases.
Several miRNAs have a role in lung diseases, such as asthma, chronic obstructive pulmonary
disease (COPD) and idiopathic pulmonary fibrosis (see Table 1). The studies reporting the
involvement of miRNAs in CF are detailed in section 3.2.2.
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Disease MicroRNAs Targets References
Asthma
miR-106a IL-10 [81]
miR-21 IL-12 [82]
miR-133a RhoA [83]
miR-26a Glycogen synthase kinase 3ß [84]
let-7 IL-13 [85]
COPD
miR-181d Interferon γ, collagen XVI αI [86]
miR-30c Proto-cadherin [86]
miR-146a Prostaglandin E2 [87]
Idiopathic pulmonary fibrosis
miR-21 SMAD7 [88]
miR-155 KGF [89]
miR-let7d HMGA2 [90]
COPD, chronic obstructive pulmonary disease.
Table 1. Examples of pulmonary diseases in which miRNAs have a role
3. Role of non-coding RNAs in the physiological regulation of CFTR gene
expression
As the function of lncRNAs has not been studied yet, we only present findings on the miRNA
roles in the regulation of CFTR gene expression.
3.1. miRNAs and CFTR gene expression
CFTR gene expression is spatially and temporally regulated. Several studies have demon‐
strated the differential use of transcription start sites, depending on the tissue type or the
developmental stage [52-55]. In the lung, CFTR transcripts can be detected early during embryo
development (12th week of pregnancy) and their level progressively increases up to the 24th
week of pregnancy. Thereafter, CFTR expression in the airways decreases and is repressed
until after birth and remains very low during adult life [56,60]. The changes in CFTR protein
expression in human foetuses are consistent with CFTR mRNA temporal pattern of expression
[60]. In a recent study, we showed that miRNAs (miR-101, miR-145, miR-384) regulate the
switch from strong foetal to very low CFTR expression after birth. Specifically, miR-101 and
miR-145 negatively regulate the level of CFTR transcripts in adult lung cells, while they have
no effect in foetal lung cells. miR-101 directly acts on its cognate site in the 3’UTR-CFTR in
combination with an overlapping AU-rich element. Other studies showed that CFTR expres‐
sion is also post-transcriptionally regulated by miRNAs, such as miR-145 and miR-494 [10,11].
Gillen et al. demonstrated that miR-145 is expressed in primary adult human airway epithelial
cells, where CFTR expression is low, and directly acts on CFTR stability [10]. In addition to its
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specific role in mature lung cells, miR-101 decreases luciferase activity in an embryonic kidney
cell line [11], whereas it does not affect CFTR mRNA stability in pancreatic cell lines [10],
suggesting a potential role as a tissue-specific factor.
3.2. Methods to investigate miRNA role in the regulation of CFTR gene expression
Different approaches can be employed to investigate miRNA role in the regulation of CFTR
gene expression, as depicted in Figure 5A.
Figure 5. Approaches for miRNA study. A. Strategies used to study the involvement of miRNAs in the regulation of
CFTR gene expression. B. Strategies to identify miRNAs that are deregulated in CF samples compared to non-CF sam‐
ples. Chips for global miRNA profiling are commercialized by Agilent, Affimetrix and Exiqon. miR-seq (miRNA se‐
quencing) is usually performed by Illumina platforms. Luc, luciferase; TLDA, TaqMan Array Micro Fluidic Cards
(Applied Biosystems); WT, wild type.
3.2.1. Predictive tools are freely available
Predictive tools are necessary to assess the putative presence of miRNA binding motifs. A non-
exhaustive list, including information about each program, is proposed in Table 2. Databases
collecting all information on miRNAs are listed in Table 3. Although miRBase (http://
www.mirbase.org/) is the most used database and collects links for several predictive pro‐
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grams, others exist. These tools have been developed to predict miRNA targets or the miRNAs
that putatively bind to a selected gene. Some of them propose the possibility to input several
miRNAs and/or several genes to identify integrated networks.
Name Website Characteristics References
TargetScan http://www.targetscan.org/Target site prediction for mammals. Secondarystructure taken into account. [91]
miRanda http://microrna.org/
Target site prediction for human, mouse, rat, fruitfly
and nematode.
Thermodynamic stability of RNA duplexes taken
into account.
[92]
PicTar http://www.pictar.org/
Algorithm for target-site prediction based on the
alignment of 3’UTR with predicted sites. Several
databases are used for vertebrates, flies, nematodes.
[93]
RNAhybrid http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/
Tool for finding the minimum free energy
hybridization for long and mainly short RNAs, such
as microRNAs to one or more given targets.
[94]
PITA
http://
genie.weizmann.ac.il/pubs/
mir07/mir07_data.html
Target-site prediction for human and other species
that evaluates the microRNA targets accessibility as
a component analysis.
[95]
miRDB http://mirdb.org/miRDB/
Tool for miRNA target-site prediction and functional
annotation based on the mirTarget algorithm for all
known human, dog, rat, and chicken transcripts.
[96]
DIANA-microT
http://
diana.cslab.ece.ntua.gr/
microT/
Target-site prediction program taking intro account
both conserved and non-conserved miRNA
regulatory elements (MREs) and providing scores as
an indication of the expected fold change in protein
production.
[97]
miRBase Target http://www.mirbase.org/
Prediction of target sites based on alignment and
conservation.
Provides links to other mains programs for miRNA
target prediction (e.g., TargetScan, PicTar).
[98]
miRTar
http://
mirtar.mbc.nctu.edu.tw/
human/
Web-based system based on the analysis of
conserved sequences (seed or 3’ miRNAs) using
external prediction tools (TargetScan, miRanda,
PITA, RNAhybrid).
Analyzes miRNA biological functions using the
KEGG pathway to draw a miRNA target interaction
network.
[99]
miRNAMap
http://
mirnamap.mbc.nctu.edu.t
w/index.php
Uses the computational tools, miRanda, RNAhybrid,
and TargetScan to identify miRNA targets in the
3’UTR of target genes.
[100]
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Name Website Characteristics References
MiRonTop http://www.microarray.fr:8080/miRonTop/index
Identification of miRNAs from DNA microarrays
and high-throughput sequencing data.
Uses several existing miRNA target prediction
approaches.
[101]
MIR@nt@n http://maia.uni.lu/mironton.php
Integrative approach for searching miRNAs target
sites, to build networks including motifs as
feedbacks and feedforward loops from lists of
molecular actors.
[102]
ProMiR http://bi.snu.ac.kr/ProMiR/
Prediction of potential conserved and non-
conserved microRNAs in a query sequence from 60
to 150 nucleotides and clusters near known or
unknown miRNAs in various species.
[103]
Table 2. Free bioinformatics tools for miRNAs
Name Website Characteristics References
miRBase http://www.mirbase.org/
Collection of annotation, literature, genomic
coordinates for human miRNAs and from several
other species.
From deep sequencing datasets, uses the pattern of
mapped reads to assess the confidence in each
miRNA annotation.
[98]
miRGen
http://
diana.cslab.ece.ntua.gr/
mirgen/
Integrated database collecting relationships between
animal miRNAs, genomic annotation sets and
miRNA targets to a combination of used target
prediction programs.
[104]
miRNAMap
http://
miRNAMap.mbc.nctu.edu.
tw/
Resource for collecting experimentally verified
microRNAs and verified miRNA target genes in
human and other metazoan genomes reducing the
false positive prediction rate of miRNA target sites.
Expression profiles by RT-qPCR of 224 human
miRNAs in 18 normal tissues.
[100]
CoGemiR http://cogemir.tigem.it/
Database offering an overview of the genomic
organization and conservation of microRNAs in
different metazoan species during evolution.
[105]
miRanda http://microrna.org/ Atlas of miRNA expression in human, mouse andrat tissues based on small RNA library sequencing.
Table 3. Free databases for miRNAs
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3.2.2. Functional approaches
To evaluate in vitro the impact of miRNAs on CFTR gene regulation, several approaches can
be used (Figure 5 A). a) First of all, in silico analysis by using bioinformatics tools can be
performed (see 3.2.1). b) The role of specific miRNAs could be assessed in vitro by using airway
cell lines and luciferase gene reporter assays, in which the luciferase coding sequence is under
the control of the 3’ UTR of CFTR, as previously described [11,3]. c) By transfecting mimics or
precursors, miRNAs can be overexpressed and the relative level of luciferase expression
reflects the effect of a given miRNA on the 3’UTR-CFTR. Inhibitors may also be used to confirm
the specific effect of the miRNA under study. d) To validate the direct effect of the identified
miRNAs (for instance, miRNA-494 and miRNA-101), the cis element for miRNAs binding in
the 3’UTR-CFTR can be mutated by site-directed mutagenesis (created mutation). Target-site
blockers may also be used to inhibit binding to the tested motif [3]. e) To validate these effects,
the endogenous level of CFTR mRNA following miRNA overexpression or down-regulation
can be assessed using different techniques.
4. Role of non-coding RNAs in CF
4.1. What is the impact of mutations in microRNA target sites on the CFTR gene?
4.1.1. Mutations in the 3’UTR of the CFTR gene
Assessing the putative impact of single nucleotide polymorphisms (SNPs) in the 3’UTR of
CFTR is essential to define the pathological importance of these cis-regulatory motifs in non-
coding regions, especially after the development of Next-Generation Sequencing (NGS)
technologies. Recent work identified the SNP c.*1043A>C on the 3’UTR of the CFTR gene in
one patient with a CFTR-related disorder and congenital bilateral absence of vas deferens [61].
This SNP is located in a region predicted to interact with miR-433 and miR-509-3p. Expression
analysis demonstrated that the c.*1043A>C mutation increases the affinity for miR-509-3p and
slightly decreases that for miR-433. In vitro, these two miRNAs reduces CFTR protein expres‐
sion. The authors suggested that the very low expression of miR-509-3p in normal human
bronchial epithelial (NHBE) cells could explain the mild phenotype caused by this mutation.
Thus, the c.*1043A>C mutation, by acting as a mild CFTR mutation that enhances the affinity
for an inhibitory miRNA, could represent a novel pathogenic mechanism in CF.
4.1.2. Methods to investigate the impact of CFTR gene mutations
Bioinformatics tools, such as miRNA binding site prediction programs (listed in Table 2), could
be used to predict whether at a mutated position there is a cis-regulatory motif and whether
it corresponds to an miRNA binding site. Moreover, tools like RNAhybrid could allow
predicting the binding energy of the mutated motif. In vitro luciferase reporter gene assays
together with mutagenesis approaches to create degenerate 3’UTR-CFTR sequences can be
used to study the different variants (Figure 5Ad).
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4.2. Deregulation of non-coding RNAs in CF
Clinical manifestations of CF are various including chronic pulmonary inflammation and
infection that strongly contribute to the morbidity and mortality of these patients [62]. Over-
inflammation precedes chronic infection that is then amplified by pathogens. Notably, the
protease–antiprotease balance, which is responsible for lung remodelling, is disrupted in CF
airways early in life and then this imbalance is chronically maintained [63]. Pulmonary tissues
in patients with CF are usually infected by antibiotic-resistant Pseudomonas aeruginosa.
Interleukin-8 (IL-8), IL-6 and Tumor Necrosis Factor alpha (TNF-alpha) are pro-inflammatory
cytokines that are highly expressed in CF lung epithelial cells and allow the recruitment of
neutrophils [62]. Lipopolysaccharide (LPS) and IL-1beta, which bind to Toll-like receptor 4
(TLR4) and IL-1R, respectively, are also involved. The identification of the molecular events
involved in lung epithelium injury and repair is essential for understanding CF physiopathol‐
ogy. Expression levels of miRNAs physiologically vary greatly among tissues. Recent advan‐
ces explored their effects on influencing signaling pathways in CF. Identification of
deregulated miRNAs may offer possible future directions for clinical applications.
4.2.1. Deregulated lncRNAs in CF
To date, only one publication has reported aberrant expression of specific lncRNAs in CF
bronchial epithelium in vivo [64]. To establish the lncRNA profiles of CF and non-CF bronchial
epithelium, 10 CF and 12 non-CF (controls) bronchial brushing samples were analyzed using
a human lncRNA Array v3.0 (ArrayStar). In this way, more than 30586 lncRNAs and 26109
protein coding transcripts were evaluated. Overall, 1063 lncRNAs, most of which were
intergenic, were differentially expressed in non-CF and CF bronchial brushing samples. RT-
qPCR analysis of the differential expression of well-known ncRNAs (XIST, MALAT1, HO‐
TAIR, and TLR8 antisense) did not confirm the down-regulation of MALAT1 and HOTAIR in
CF samples compared to controls. Interestingly, MALAT1 (lnc-SCYL1-1*) and HOTAIR (lnc-
SMUG1-7*) have been described as oncogenic lncRNAs in lung cancer (*asterisks meaning the
existence of several isoforms).
4.2.2. Deregulated miRNAs in CF
miRNA profiling studies identified various miRNAs with altered expression in CF (summar‐
ized in Figure 6). For instance, in vivo the expression of miR-145, miR-223 and miR-494 is
increased in CF bronchial brushing samples (individuals with at least one p.Phe508del CFTR
allele) compared to non-CF controls and correlates with decreased p.Phe508del CFTR
expression. Moreover, these three miRNAs inhibit CFTR mRNA expression [65]. These authors
also highlighted a relationship between their regulation and CFTR chloride channel activity.
Specifically, they showed that treatment with inh-172, a specific inhibitor of the CFTR chloride
channel, significantly increases the level of miR-145, miR-223 and miR-494 in 16 HBE14o-
respiratory epithelial cells. These data are in agreement with the hypothesis by Wenming Xu
et al. [66] that CFTR chloride channel alteration affects the miRNA profile. Another study
reported that miR-509-3p and miR-494 are increased in well-differentiated primary cultures
of human CF but not of non-CF airway epithelia, [67]. Other miRNAs have been found to be
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deregulated in CF, such as miR-155, miR-126 and miR-31 [68]. miR-155 is overexpressed in
IB3-1 CF cells compared to IB3-1 control cells and in ex vivo CF cells (bronchial brushing
samples versus normal human bronchial epithelial cells and CF neutrophils CD66+ versus
control cells). Moreover, in IB3 cells, miR-155 up-regulation is related to defective CFTR
chloride channel activity (following exposure to inh-172). This leads to repression of SHIP1, a
well-known effector in the regulation of inflammation, and consequently to activation of the
PI3K/AKT pathway that stabilizes IL-8 mRNA through MAPK. Thus, miR-155 up-regulation
contributes to the maintenance of a pro-inflammatory phenotype. Furthermore, miR-155-
antagomir leads to IL-8 down-regulation in IB3-1CF cells and could represent a candidate
treatment for CF. The biogenesis of miR-155 has been in part elucidated and involves the
inflammatory RNA binding proteins KSRP and TTP [69]. KSRP promotes miR-155 production,
while TTP down-regulates, via miR-1, miR-155 mature expression in CF lung epithelial cells.
CF vs non CF 
bronchial 
       brushing 
ALI* culture of CF vs non CF 
airway epithelia 
(trachea and primary bronchi) 
 miR-494 
 miR-509-3p 
 miR-138 
 
IB3-1 CF vs  
IB3/S9  miR-155 
 miR-126 
 
CFBE41o- vs 
16HBE14o- 
miR-126 
miR-146-a CF vs non CF 
Nasal cavity 
brushing 
 miR-145 
 miR-494 
 
 miR-101 
 miR-138 
 miR-145 
     miR-223          
          miR-494 
 
          miR-145 
      miR-223          
    miR-494 
miR-126 
 
miRNA 
dysregulation in CF 
airways 
Figure 6. Deregulated miRNAs in different CF models. The schematic lists miRNAs that have been reported to be up-
regulated or down-regulated in CF (tissues, cell lines, primary cultures) versus (vs) non-CF samples. *ALI: Air–Liquid
Interface.
Conversely, miR-126 down-regulation has an anti-inflammatory role to compensate the
immunity response. Oglesby et al. [70] reported that miR-126 is consistently decreased in CF
compared to non-CF airway epithelial cells and this reduction correlates with up-regulation
of TOM1, a negative regulator of TLR2, TLR4, IL-1, IL-1β and TNF-alpha [71,72]. TOM1, which
also negatively regulates NF-κB, may play an anti-inflammatory role in CF lung. The authors
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hypothesized that the observed reduction in miR-126 expression in CF cells may be due to ER
stress induced by accumulation of misfolded p.Phe508del CFTR proteins. A complete analysis
of the pathways triggered in CF cells seems essential to identify/develop novel treatments for
CF.
Another study assessed the miRNA profile, by using Agilent microarray, of CF IB3-1 cells
infected or not with Pseudomonas aeruginosa, a model mimicking the inflammatory response
observed in pulmonary tissues of CF patients [73]. Two miRNAs (miR-93 and miR-494) were
found to be strongly deregulated in infected cells. These two miRNAs are predicted to interact
with the 3’UTR of IL-8 mRNA. Down-regulation of miR-93 was confirmed in two other
bronchial epithelial cell lines (CF CuFi-1 and non-CF Nuli-1 cells). In non-infected CF cells,
miR-93 is strongly expressed and is involved in IL-8 down-regulation combined with low NF-
κB recruitment to the IL-8 promoter. In CF cells infected with Pseudomonas aeruginosa, the
combined effects of high NF-κB recruitment to the IL-8 gene promoter and miR-93 down-
regulation lead to high IL-8 expression [73].
Finally, miR-31 is down-regulated in CF bronchial brushing cells compared to non-CF cells
[74]. In CF epithelial cells, miR-31 negatively modulates the expression of IRF1, a transcription
factor that regulates the level of cathepsin S (CTSS). CTSS is overexpressed in CF airways cell
lines, such as bronchial (CFBE), tracheal (CFTE) and CF primary bronchial epithelial cells (CF-
PBECs) and has been detected in CF lung secretions. CTSS activates the epithelial sodium
channel and cleaves and inactivates antimicrobial proteins such as surfactant A, lactoferrin
and members of the β-defensin family, thus contributing to lung inflammation in patients with
CF [63-66]. Moreover, in a cohort of paediatric patients with CF, it was found that CTSS level
correlates with the decline of lung function. Thus, miR-31 is a potential regulator of CTSS
expression via IRF1 in CF epithelial cells [74].
4.2.3. Methods to study deregulated non-coding RNA
Methods to quantify miRNAs in CF and non-CF samples are depicted in Figure 5B. Approaches
to identify dysregulated lncRNAs in CF samples are detailed in Figure 7 and databases for
lncRNAs are listed in Table 4.
Name Website Characteristics References
LNCipedia http://www.lncipedia.org/
Integrated database of human lnc transcripts.
Specific annotation of lncRNAs. Algorithms to
assess the protein-coding potential of transcripts.
LncRNA gene conservation between human, mouse
and zebrafish.
[106,107]
lncRNA2Target http://www.lncrna2target.org/
Curated database with human lncRNA-to-target
gene. Target genes based on overexpression and
knockdown studies.
[108]
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Name Website Characteristics References
lncRNAWiki http://lncrna.big.ac.cn/index.php/Main_Page
Component of ScienceWiki for community curation
of human lncRNAs. [109]
lncRNAdb http://www.lncrnadb.org/
Database for functional eukaryotic lncRNAs. Allow
blast search of putative lncRNAs.
Gene expression data, evolutionary conservation,
structural information, genomic context, subcellular
localization, functional evidence.
[110,111]
NONCODE http://www.noncode.org/
Integrated knowledge database dedicated to
ncRNAs. NONCODE specific ID for each ncRNA
with a conversion tool to RefSeq and Ensembl.
Includes all ncRNAs, except transfer RNAs and
ribosomal RNAs, ncRNA sequences and relative
information (expression, cellular location,
chromosomal information...). More than 80% of
entries are based on literature data.
[112,113]
NRED : ncRNA
expression
database
http://
nred.matticklab.com/cgi-
bin/ncrnadb.pl
Gene expression repository for human and mouse
lncRNAs.
Includes both microarrays and in situ hybridization
data.
Includes evolutionary conservation, secondary
structure, genomic context.
[114]
GENCODE http://www.gencodegenes.org/
Human lncRNAs catalog from manually annotated
genes
Data available via the UCSC Genome Browser
[119]
Human Body
Map lincRNAs
http://
www.broadinstitute.org/
genome_bio/
human_lincrnas/
Human reference catalog for lincRNAs
Expression data from RNAseq accross 24 tissues
and cell types.
lincRNA features (sequence, structure,
transcriptional and orthology features).
[115]
fRNAdb http://www.ncrna.org/frnadb
Database containing a large collection on non-
coding transcripts including annotated and non-
annotated sequences from the H-inv database,
NONCODE and RNAdb databases.
[116]
NPInter http://www.bioinfo.org/NPInter/index.php
Database integrating the diverse body of
experimental knowledge on functional interactions
between ncRNAs (except tRNAs and rRNAs) and
protein-related biomacromolecules such as proteins,
mRNA of genomic RNAs.
Functional interactions (both physical interactions
and other forms of interactions) eliciting a cellular
reaction.
[117]
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Name Website Characteristics References
lnCeDB http://gyanxet-beta.com/lncedb/
Database of lncRNAs acting as competing
endogenous RNAs. Putative interactions between
lncRNAs and mRNA targets using algorithms and
in silico tools such as StarBase.
[118]
lncRbase
http://
bicresources.jcbose.ac.in/
zhumur/lncrbase/
Comprehensive database of human and mouse
lncRNAs.
Contains genomic location, overlapping small
ncRNAs, associated repeat elements and imprinted
genes and lncRNA promoter information.
[119]
Table 4. Free databases for lncRNAs
Figure 7. Strategies to study lncRNAs in CF and non-CF samples. Few techniques allow the quantitative analysis of
lncRNAs in biological samples. RNAseq: global sequence screening is currently an easy option thanks to NGS and
small RNA sequencing. This method allows detecting and quantitating in a biological sample all non-coding tran‐
scripts. However, as lncRNAs are very weakly expressed, this strategy might not be fully appropriate. To obtain a sig‐
nificant profile of ncRNAs, more than 180 million reads are required, whereas for protein-coding transcripts, less than
30 million are needed. Therefore, microarray analysis remains a powerful tool for global profiling of lncRNAs. In total,
more than 30,586 lncRNAs have been analyzed based on the last lncRNA databases. AONs: antisense oligonucleotides.
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4.3. Impact of mutations in lncRNA or miRNA genes
To date, no ncRNA mutation has been described in CF. However, alterations in RNA sequence
and/or structure can affect the synthesis, maturation and turnover of ncRNAs. Changes in
RNA molecules can be introduced in different ways. For instance, SNPs may affect miRNA
biogenesis. miRNA tailing can modify pre-miRNAs and mature miRNAs. RNA editing can
modify nucleotide sequences of RNA transcripts. NGS technologies, including exome se‐
quencing and complete re-sequencing of the CFTR gene, could reveal mutations in lncRNA
sequences that may affect CF severity and outcome.
5. Targeting miRNA as new putative therapeutic tool
5.1. Could miRNAs help in improving CF treatment?
A recent work demonstrated that miR-138 mimics might restore CFTR-Phe508del expression
and functional chloride transport. However, the authors stressed that miR-138 mimics may
also have undesired effects, because miR-138 targets SIN3A, a highly conserved transcriptional
repressor that regulates many genes [67]. Another anti-miRNA agent has been exploited as
inhibitor of miR-509-3p, which is involved in the regulation of the CFTR gene. Recently, we
reported that miRNA function can be blocked by targeting the CFTR gene with blockers. We
designed blockers to prevent the binding of several miRNAs specifically to the 3’UTR-CFTR
and tested them in well-differentiated primary human nasal epithelial cells from healthy
individuals and patients with CF carrying the p.Phe508del CFTR mutation. These molecules
rescued CFTR chloride channel activity by increasing CFTR mRNA and protein levels. This is
in agreement with previous studies showing that complementation of just 6–10% of CFTR
transcripts leads to the production of enough CFTR to maintain normal chloride transport in
epithelia [75]. These data are supported by findings that the presence of a naturally occurring
sequence variation in the CFTR promoter, in cis of a severe mutation, increases transcription.
This allows the production of enough CFTR protein to reach the apical membrane cells and
partially restore CFTR channel function, thus leading to a moderate CF phenotype despite the
presence of a severe disease-causing mutation [76]. Similarly, stabilization of p.Phe508del
CFTR protein has been associated with increased p.Phe508del CFTR channel activity [77].
5.2. Assays and molecules
As depicted in Figure 5Ad, inhibitors or target-site blocker oligonucleotides have been
previously used to restore CFTR expression. Tests have been performed by incorporating
inhibitors that induce degradation of the targeted endogenous miRNA or with oligonucleoti‐
des that block miRNA binding to the 3’UTR of CFTR in cell lines, primary cultures and
reconstituted epithelium
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6. Conclusion and remarks
The identification of cis- and trans-regulators and pathways involved in CFTR gene expression
is essential for developing new CF targeted therapies. Over the past four decades, therapies
for CF have focused entirely on symptoms to improve patients’ quality of life. The first
treatment (VX-770) targeted the basic defect in p.Gly551Asp-CFTR (1.6% of patients with CF
worldwide) [78]. The new molecule VX-809 has been evaluated in patients carrying the
p.Phe508del CFTR mutation; however, on its own it does not have clear effects [79] and clinical
trials testing the combination of different molecules are in progress. The mechanisms respon‐
sible for the phenotype severity are not well understood yet. Mutational heterogeneity and
complex alleles influence CF severity. Moreover, the role of few modifier genes has been
established [80]. ncRNAs could also contribute to CF progression and severity and their
dysregulation in CF opens new perspectives for patient follow-up and treatment.
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